IN the 1963 to 1964 rubella epidemic in the United States 20,000 children were born with birth defects, with an additional 8,000 to 30,000 fetal deaths attributed to the virus. That this may not have to happen again is the promise of rubella vaccination which four years of trial have demonstrated to be as safe and effective as measles vaccine.1 Two strains of rubella vaccine are being produced commercially: the H.P.V. 77 strain of rubella vaccine developed at the National Institute of Health, and the Cendehill strain developed in Belgium. Trials with these vaccine strains have shown no side-effects when given to children. On the other hand possible risks of teratogenicity when the vaccine is given to pregnant or about-to-become-pregnant women remains to be determined. Therefore, serologic tests to separate the 85% to 90% of women already immune need to be standardized to select the 10% to 15% of childbearing-age
Rubella Vaccination. Arch Otolaryngol. 1969;90(1):3. doi:10.1001/archotol.1969.00770030005003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.